Advertisement

Organisation › Details
Cytokinetics Inc. (Nasdaq: CYTK)
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next- generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3 pending ongoing regulatory interactions. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness. *
![]() |
Start | 1998-12-16 established |
![]() |
Industry | small-molecule drug |
Industry 2 | cardiovascular drug | |
![]() |
Region | South San Francisco, CA |
Country | United States (USA) | |
Street | 280 East Grand Avenue | |
City | 94080 South San Francisco, CA | |
Tel | +1-650-624-3000 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Cytokinetics, Inc.. (12/23/20). "Press Release: Cytokinetics Regains European Rights to Omecamtiv Mecarbil". South San Francisco, CA. | ||
Record changed: 2020-12-25 |
Advertisement

More documents for Cytokinetics Inc. (Nasdaq: CYTK)
- [1] Cytokinetics, Inc.. (12/23/20). "Press Release: Cytokinetics Regains European Rights to Omecamtiv Mecarbil". South San Francisco, CA....
- [2] Cytokinetics, Inc.. (11/23/20). "Press Release: Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 from Amgen". South San Francisco, CA....
- [3] Smith, Jonathan. (12/14/18). "News: This Company Is Strengthening Muscles in Neuromuscular Disorders. Biotech of the Week – NMD Pharma"....
- [4] Roche. (6/22/18). "Press Release: Changes to the Roche Enlarged Corporate Executive Committee". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top